On 14th November, NHS England hosted their Histopathology Transformation and Recovery event, supported by the Royal College of Pathologists and the Institute of Biomedical Science. BIVDA’s Paul Fisher, Head of Policy, Programmes and Compliance attended.
The event clearly showed the key role of pathology services across the whole spectrum of health and the NHS’s clear commitment to transformation, with stretching targets for pathology services to deliver by March 2025. The challenges are systemic, meaning system actors (including the in vitro diagnostic industry) are the only solution.
As set out in the Richards Review, the key enabler is getting the diagnostics pathway right – including by moving pathology services from traditional locations to be closer to the user, new service models, and increased use of digital pathology. With workforce a challenge, and many pathology networks significantly understaffed, automation, digitalisation, and the use of artificial intelligence are key enablers the IVD industry is well-placed to support.
Paul said: ‘The IVD industry is innovative, agile, and passionate about improving patient outcomes. It is ideally placed to support the NHS’s transformation and recovery plans. BIVDA knows that access to the NHS can be challenging, and members report difficulties in getting their products into clinical pathways in a timely fashion.
‘With this in mind, BIVDA will be launching a Task and Finish Sub-Group looking to support the Histopathology Transformation and Recovery plan, by advocating for more agile procurement, better links between industry and the NHS, and continuing our activities to ensure the UK government create an environment where innovation can flourish.’